/SGMT
SGMT Stock - Sagimet Biosciences Inc.
Healthcare|BiotechnologyNASDAQ
$6.28+5.37%
+$0.32 (+5.37%) • Dec 19
33
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.36
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).41
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-4.5%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SGMT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.22 – $6.34
TARGET (TP)$6.00
STOP LOSS$5.78
RISK/REWARD1:-0.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.37
52W High$11.41
52W Low$1.73
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $2.00M | N/A | N/A | N/A |
| Gross Profit | N/A | $2.00M | N/A | N/A | N/A |
| Gross Margin | N/A | 100.0% | N/A | N/A | N/A |
| Operating Income | $-54,454,000 | $-30,740,000 | $-31,055,000 | $-23,719,000 | $-11,400,000 |
| Net Income | $-45,567,000 | $-27,876,000 | $-30,499,000 | $-24,442,000 | $-11,370,000 |
| Net Margin | N/A | -1393.8% | N/A | N/A | N/A |
| EPS | $-1.45 | $-1.53 | $-1.38 | $-1.10 | $-0.51 |
Company Overview
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
91%
Hold / Neutral
1
9%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish1 Neutral/Bearish
Price Targets
$29
Average Target
↑ 364.7% Upside
Now
$6
Low
$29
Average
$67
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 11th 2025 | Wedbush | Initiation | Outperform | $28 |
| August 7th 2025 | H.C. Wainwright | Resumed | Buy | $29 |
| July 24th 2025 | Canaccord Genuity | Initiation | Buy | $28 |
| December 6th 2024 | Oppenheimer | Initiation | Outperform | $30 |
| November 12th 2024 | UBS | Initiation | Buy | $12 |
| June 28th 2024 | Goldman | Downgrade | Neutral | $6← $23 |
| May 2nd 2024 | H.C. Wainwright | Initiation | Buy | $32 |
| March 25th 2024 | Leerink Partners | Initiation | Outperform | $26 |
| August 8th 2023 | TD Cowen | Initiation | Outperform | - |
| August 8th 2023 | Piper Sandler | Initiation | Overweight | $67 |
| August 8th 2023 | Goldman | Initiation | Buy | $33 |
| August 8th 2023 | JMP Securities | Initiation | Mkt Outperform | $30 |
Earnings History & Surprises
SGMTBeat Rate
80%
Last 10 quarters
Avg Surprise
-686.1%
EPS vs Estimate
Beats / Misses
8/2
Last 12 quarters
Latest EPS
$-0.40
Q4 2025
EPS Surprise History
Q1 24
-34.5%
$-0.78vs$-0.58
Q2 24
+43.9%
$-0.23vs$-0.41
Q3 24
+26.5%
$-0.25vs$-0.34
Q4 24
+4.3%
$-0.45vs$-0.47
Q1 25
+23.1%
$-0.50vs$-0.65
Q2 25
+29.1%
$-0.56vs$-0.79
Q3 25
+38.5%
$-0.32vs$-0.52
Q4 25
+2.4%
$-0.40vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 11, 2026 | $-0.43 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.52 | $-0.32 | +38.5% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.79 | $-0.56 | +29.1% | ✓ BEAT |
Q1 2025 | Mar 12, 2025 | $-0.65 | $-0.50 | +23.1% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.47 | $-0.45 | +4.3% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.34 | $-0.25 | +26.5% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.41 | $-0.23 | +43.9% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-0.58 | $-0.78 | -34.5% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-1.02 | $-0.35 | +65.7% | ✓ BEAT |
Q3 2023 | Jul 14, 2023 | $-0.50 | $-35.80 | -7060.0% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $-0.30 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.32 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.34 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.32 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.39 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.25 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.18 | — | — |
Latest News
Sagimet Reports MASH Combo Data, Eyes Phase 2 for Liver Treatment
📈 PositiveBenzinga•Dec 18, 2025, 12:03 PM
Sagimet Biosciences shares are trading higher after the company announced a license agreement with Teva subsidiary TAPI for Resmetirom API.
📈 PositiveBenzinga•Dec 17, 2025, 05:19 PM•Also:
Sagimet Biosciences Announced A License Agreement With A Subsidiary Of Teva Pharmaceutical
📈 PositiveBenzinga•Dec 17, 2025, 12:06 PM•Also:
Sagimet Biosciences Says Ascletis Gets China NMPA NDA Acceptance For Denifanstat ASC40, First-In-Class Oral FASN Inhibitor For Moderate-To-Severe Acne After Phase III Trial Meets All Primary And Key Secondary Endpoints
📈 PositiveBenzinga•Dec 10, 2025, 10:41 AM•Also:
Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $35
📈 PositiveBenzinga•Nov 14, 2025, 03:28 PM
Sagimet Biosciences shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 13, 2025, 08:06 PM
Sagimet Biosciences Q3 EPS $(0.40) Beats $(0.42) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 12:36 PM
Sagimet Biosciences Presents Denifanstat Phase 2b Results Highlighting Advanced Fibrosis And Biomarker Improvements At AASLD 2025
📈 PositiveBenzinga•Nov 10, 2025, 12:19 PM
Sagimet Biosciences shares are trading higher after the company announced Denifanstat achieved all primary and secondary endpoints and was generally well tolerated in phase 3 clinical trial in acne in China.
📈 PositiveBenzinga•Oct 24, 2025, 05:57 PM
Sagimet Biosciences Announces Denifanstat Achieved All Primary And Secondary Endpoints And Was Generally Well Tolerated In Phase 3 Clinical Trial In Acne In China
📈 PositiveBenzinga•Oct 24, 2025, 11:05 AM
Clear Street Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $29
📈 PositiveBenzinga•Oct 22, 2025, 11:14 AM
Sagimet Biosciences To Showcase FASCINATE-2 Study Results On Denifanstat's Fibrosis Improvement In Advanced MASH At Liver Meeting 2025
📈 PositiveBenzinga•Oct 7, 2025, 11:14 AM
Canaccord Genuity Maintains Buy on Sagimet Biosciences, Maintains $28 Price Target
📈 PositiveBenzinga•Oct 2, 2025, 12:25 PM•Also:
Sagimet Doses First Participants In Phase 1 Pharmacokinetic Trial Of Combination Of Oral Once-Daily FASN Inhibitor, Denifanstat, And THR-β Agonist, Resmetirom; Topline Data Expected In H1 2026
➖ NeutralBenzinga•Oct 1, 2025, 11:17 AM
Sagimet Confirms Phase 3 Denifanstat Success In Moderate To Severe Acne With EADV 2025 Oral Presentation In Paris Scheduled
📈 PositiveBenzinga•Sep 17, 2025, 11:16 AM
Sagimet To Present New MASH Research And Join Drug Development Panel At Boston Summit
📈 PositiveBenzinga•Sep 10, 2025, 11:10 AM
Sagimet Biosciences Tops Q2 EPS Forecast
📈 PositiveThe Motley Fool•Aug 13, 2025, 11:48 AM
Sagimet climbs as acne therapy hits main goals in late-stage trial in China
📈 PositiveSeeking Alpha•Jun 4, 2025, 10:54 AM
Frequently Asked Questions about SGMT
What is SGMT's current stock price?
Sagimet Biosciences Inc. (SGMT) is currently trading at $6.28 per share. The stock has moved +5.37% today.
What is the analyst price target for SGMT?
The average analyst price target for SGMT is $6.00, based on 1 analyst.
What sector is Sagimet Biosciences Inc. in?
Sagimet Biosciences Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SGMT's market cap?
Sagimet Biosciences Inc. has a market capitalization of $0.19 billion, making it a small-cap company.
Does SGMT pay dividends?
No, Sagimet Biosciences Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHV
Achieve Life Sciences, Inc.
$4.32
Mkt Cap: $0.2B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
ASMB
Assembly Biosciences, Inc.
$35.26
Mkt Cap: $0.3B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
ZURA
Zura Bio Limited
$4.27
Mkt Cap: $0.3B
Explore stocks similar to SGMT for comparison